HomeInvestors & MediaNews
ABL Bio, Completed patent registration for ABL503 in Japan following Chile and South Africa
- Guarantee of right in Japan for ‘ABL503 and its use’ by 2039- Japan is regarded as major market in that cancer is the number one cause of death for Japanese. ABL Bio (CEO Sanghoon Lee) specializing in BsAb (Bispecific Antibody) company announced that it has completed patent (name of patent: anti-PD-L1/anti-4-1BB bispecific antibody and its use) registration in Japan for the immuno-oncology ABL503 on date. The patent in Japan was third registration after Chile and South Africa, and It is guaranteed its right until 2039. In addition, patent examination is in progress in more than 20 countries, including the United States, China and Europe. ABL503, which is under joint development with Nasdaq-listed company I-Mab, was developed to target PD-L1 and 4-1BB at the same time to overcome the limitation of prior PD-(L)1 mechanism based immuno-oncology that shows effect only for 20% of total patients. PD-L1x4-1BB is the one of BsAb models that is raising expectations because many global bio companies are conducting clinical trials for it including Genmab that already has 7 approved antibody drugs. In this competitive situation, ABL503 secured competitiveness by applying ABL Bio’s Grabody-T technology which makes it possible to have optimal epitope binding for 4-1BB activation. It has been verifying its superiority by showing great safety profile at higher dose than valid dose of other PD-L1x4-1BB BsAb pipelines in its ongoing clinical trial in US and South Korea. "Entering an super-aged society where the elderly population aged 65 or older accounts for nearly 30% of the total population, Japan’s national level of interest and support for national health are active, and especially cancer is the number one major cause of death for Japanese" said Sanghoon Lee CEO of ABL Bio. “As a PD-(L)1 mechanism based immuno-oncology that is effective in more than 20 indications, ABL503 is expect to have high competitiveness in the Japanese anticancer market in the future” he added. Meanwhile, ABL Bio's more than 6 pipelines such as ABL001(VEGFxDLL4), ABL111(Claudin18.2x4-1BB), ABL503(PD-L1x4-1BB), ABL105(HER2x4-1BB), ABL202(ROR1 ADC), ABL301(a-synxIGF1R) etc. are under global clinical trial by ABL Bio or by its partners in the US, China, Australia and Korea. Pipelines such as ABL103(B7-H4x4-1BB) and ABL104(EGFRx4-1BB) etc. are also under preparation to enter clinical trials by ABL Bio or by its partners. In addition, a number of non-clinical pipelines including ABL602(CLL1xCD3) are also actively underway.
2023-08-09ablbio
I-Mab, published manuscript of ABL111(TJ-CD4B) under co-development with ABL Bio on the inte...
- Demonstrated anti-tumor effect on CLDN18.2-expressing tumor through 4-1BB mediated T cell activation- Expected to be innovative treatment for gastric cancer patients that show a poor prognosis and have limited treatment options Nasdaq listed company I-Mab announced on date that it published manuscript of ABL111(TJ-CD4B, Givastomig) under co-development with ABL Bio on JITC(The journal for ImmunoTherapy of Cancer) which is official journal of SITC(Society for Immunotherapy of Cancer). Manuscript explains about anti-tumor effect of CLDN18.2x4-1BB BsAb Givastomig(hereafter ABL111) that is induced by activating T cell specifically at tumor expressing CLDN18.2, and original title is “Claudin18.2 and 4-1BB bispecific antibody Givastomig exerts anti-tumor activity through CLDN18.2-expressing tumor-directed T cell activation”. ABL111 which targets and binds to CLDN18.2 and 4-1BB at the same time induces potent tumor-killing effect by activating T cell specifically within CLDN18.2-expressing tumor. It is assessed as innovative approach to improve treatment effect in immunotherapy of gastric cancer which shows a poor prognosis and has limitation for treatment options. According to the results of the study, ABL111 binds to CLDN18.2 from low to high expression level and indicated the targeted effect by inducing 4-1BB activation only when it binds to CLDN18.2. Also, in in vivo model, ABL111 showed superior anti-tumor activity and long-lasting inhibition against tumor rechallenge by increasing CD8/Treg cell rate within tumors through immune activation. “The findings from our research demonstrate the significant potential of givastomig in treating gastric cancer patients with varying levels of CLDN18.2 expression,” said Dr. Lin Shen, Professor of Clinical Oncology at the Beijing Cancer Hospital of Peking University, Director of SIP LifeLink Oncology Research Institute, and principal investigator of the first-in-human study of givastomig (NCT04900818). “By activating 4-1BB signaling in a CLDN18.2 engagement-dependent manner, givastomig can avoid the risk of liver toxicity and systemic immune response commonly observed with other 4-1BB stimulating agents in previous clinical trials.” “We are excited to see this manuscript published in JITC, as it showcases the innovative design and remarkable anti-tumor activity in preclinical models of givastomig,” said Dr. Andrew Zhu, President of I-Mab. “This bispecific antibody has demonstrated promising results in preclinical models and ongoing clinical study by effectively activating T cells and triggering a localized immune response within the tumor microenvironment. With ongoing clinical studies, we aim to build upon these findings and ultimately make this innovative therapy accessible to patients with gastric cancer.” “It is glad that immuno-oncology pipeline ABL111’s great efficacy got recognized and introduced through international journal” said Sanghoon Lee, CEO of ABL Bio. “We will keep our active academic activity with ongoing clinical trials including ABL503’s Korea phase 1 expansion and ABL103’s Korea phase 1 that both were began in 2023” he added. ABL111’s clinical trial phase 1 is in progress smoothly in US and China, and it is encouraging that it has shown favorable safety profile and promising efficacy so far in phase 1. Clinical data will be disclosed at major medical conferences by I-Mab within the second half. Meanwhile, ABL Bio's more than 6 pipelines such as ABL001(VEGFxDLL4), ABL111(Claudin18.2x4-1BB), ABL503(PD-L1x4-1BB), ABL105(HER2x4-1BB), ABL202(ROR1 ADC), ABL301(a-synxIGF1R) etc. are under global clinical trial by ABL Bio or by its partners in the US, China, Australia and Korea. Pipelines such as ABL103(B7-H4x4-1BB) and ABL104(EGFRx4-1BB) etc. are also under preparation to enter clinical trials by ABL Bio or by its partners. In addition, a number of non-clinical pipelines including ABL602(CLL1xCD3) are also actively underway.
2023-07-06ablbio
ABL Bio, Completed patent registration for ABL503 in Chile & South Africa
- Guarantee of rights in each country for ABL503 and its use by 2039- Multinational patent acquisition adds flexibility to clinical and commercialization strategies ABL Bio (CEO Sanghoon Lee) specializing in BsAb (Bispecific Antibody) company announced that it has completed patent (name of patent: anti-PD-L1/anti-4-1BB bispecific antibody and its use) registration in Chile and South Africa for the immuno-oncology ABL503 on date. These patents are guaranteed their rights until 2039. In addition, patent examination is in progress in more than 20 countries, including the United States, China, Europe, and Japan. ABL503, which is under joint development with Nasdaq-listed company I-Mab, is a BsAb pipeline that targets PD-L1 and 4-1BB at the same time. In the case of PD-(L)1 mechanism-based blockbuster drug Keytruda, it is widely applicable to more than 20 kinds of cancer, but there is still a limitation that it is effective for only 20% of total patients. ABL503, developed to overcome the limitation of these PD-(L)1 mechanism-based immuno-oncology, is a BsAb that combines PD-L1 target antibody with 4-1BB target antibody, and is designed to show improved efficacy by enhancing immune cell activity and adding memory T-cell activation. ABL503’s phase 1 clinical trial is progressing smoothly in the United States and South Korea, also it is expected to have differentiated strength in searching optimal dose with great safety profile at higher dose than valid dose of other companies’ PD-L1x4-1BB BsAb phase 2. "In the case of pure R&D-based biotech company like ABL Bio, the protection of intellectual property rights including patents, is as important as R&D of new drugs," said Sanghoon Lee CEO of ABL Bio. “Patent registration in various countries will also create more opportunities and flexibility in establishing clinical and commercialization strategies for new drug pipelines in the future” he explained the meaning of patent registration. Meanwhile, ABL Bio's more than 6 pipelines such as ABL001(VEGFxDLL4), ABL111(Claudin18.2x4-1BB), ABL503(PD-L1x4-1BB), ABL105(HER2x4-1BB), ABL202(ROR1 ADC), ABL301(a-synxIGF1R) etc. are under global clinical trial by ABL Bio or by its partners in the US, China, Australia and Korea. Pipelines such as ABL103(B7-H4x4-1BB) and ABL104(EGFRx4-1BB) etc. are also under preparation to enter clinical trials by ABL Bio or by its partners. In addition, a number of non-clinical pipelines including ABL602(CLL1xCD3) are also actively underway.
2023-07-05ablbio
ABL Bio, collaborate with global No.1 CDMO Lonza… to spur development and manufacturing
- Increased efficiency and stability of bispecific antibody manufacturing with diversification of CDMO- Acceleration of clinical preparation is expected with End to End Solution ABL Bio (CEO Sanghoon Lee), a company specializing in bispecific antibody, announced that it has signed a collaboration contract with Lonza (Switzerland), the global No. 1 biopharmaceutical CDMO company, for the development and manufacturing of bispecific antibodies. With Lonza supporting the End-to-End Solution, the two companies will work closely together from the initial DNA stage to IND for ABL Bio pipelines. If GS Xceed®, a unique gene expression technology of Lonza, is applied to ABL Bio's bispecific antibody manufacturing, which has already been proven to have advanced technology with its clinical data and license-out experiences, effective and stable manufacturing of high-quality antibodies can be expected. Jennifer Cannon, Global Head of Mammalian Biologics, Lonza commented “With the biologics pipeline evolving towards more complex protein formats, bi- and multi-specific molecules are a growing part of Lonza’s portfolio. For more than 35 years, our teams have built extensive experience and capabilities in this area, and we are committed to supporting our customers in their unique journey to IND. This collaboration will provide ABL Bio with greater flexibility and speed on the path to commercialization. We look forward to working together to bring this innovative therapeutic antibody candidate one step closer to patients.” Sanghoon Lee, ABL Bio CEO, said "This collaboration with Lonza, the world's No. 1 CDMO company, is another leap forward of ABL Bio to become a global top-tier bio company” and added, “As Lonza’s CDMO service is not limited to bispecific antibodies, ABL Bio will diversify its next-generation pipelines such as ADCs to increase growth potential and lead the antibody field.” Meanwhile, ABL Bio's more than 6 pipelines such as ABL001(VEGFxDLL4), ABL111(Claudin18.2x4-1BB), ABL503(PD-L1x4-1BB), ABL105(HER2x4-1BB), ABL202(ROR1xADC), ABL301(a-synxIGF1R) etc. are under global clinical trial in the US, China, and Korea. Pipelines such as ABL103 (B7-H4x4-1BB) and ABL104 (EGFRx4-1BB) etc. are also under preparation to enter clinical trials. In addition to the number of non-clinical pipelines, including ABL603(Claudin18.2xCD3) and ABL602(CLL1xCD3), are also actively underway.
2023-04-04ablbio
ABL Bio, bispecific antibody immuno-oncology ABL 503’s Korea phase 1 IND was approved
- Phase I clinical trial in the U.S. is on the right track.- With superior safety, advantageous in verifying optimal dose over competitors ABL Bio (CEO Sanghoon Lee), a company specializing in bispecific antibody, announced on the xth that it has got approval from the Ministry of Food and Drug Safety (MFDS) for the phase 1 IND of the bispecific antibody immuno-oncology ABL503. ABL503 will expand the phase 1 clinical trial to Korea which is ongoing at 6 clinical institutions in the United States. Hereafter, ABL Bio will get the additional safety data in monotherapy and determine the recommended dose (RP2D) and optimal target cancer for phase 2 clinical trials through the dose expansion part clinical trial. Both ABL503 and ABL111, which are being jointly developed with NASDAQ-listed I-Mab, are on the right track for their phase 1 clinical trial in the US and are showing good clinical results. Bispecific antibody ABL503, which targets PD-L1 and 4-1BB at the same time, selectively activates T cells only in tumor microenvironments. Since 4-1BB can be activated only in immune cells around cancer cells expressing PD-L1. Therefore, it is possible to minimize the side effects of 4-1BB that shows high hepatotoxicity when used as a monoclonal antibody. This is why ABL503 is drawing attention as a new alternative to the existing treatment, which had therapeutic effects for only 20-30% of patients on licensed immune checkpoint inhibitory anticancer drugs, and did not have a treatment with new mechanism in case of recurrence. In particular, considering the interim results of the ongoing clinical trial, ABL503 has a wide range for drug effect verification compared to competitors of the same target based on excellent safety, which is regarded as advantage compared to competitors. Sanghoon Lee, ABL Bio CEO, said "In 2023, we will announce good interim clinical result of existing pipelines as well as news of new pipeline clinical trial initiations” and added “Since ABL Bio’s pipelines are designed to have differentiation with existing competitors, I’m confident that their value will be fairly evaluated if good clinical results continue to be supported." Meanwhile, along with ABL503(PD-L1x4-1BB), ABL Bio's 7 pipelines such as ABL001(VEGFxDLL4), ABL111(Claudin18.2x4-1BB), ABL105(HER2x4-1BB), ABL202(ROR1 ADC), ABL301(a-synxIGF1R) etc. are on global clinical trial in the US, China and Korea. 3 pipelines, ABL103(B7-H4x4-1BB), ABL104(EGFRx4-1BB), and ABL101(BCMAx4-1BB), are also preparing for clinical entry. In addition to the 10 pipelines, R&D of a number of non-clinical pipelines, including ABL603(Claudin18.2xCD3) and ABL602(CLL1xCD3), are also actively underway.
2023-03-30ablbio
ABL Bio enters the phase 1 expansion part of global clinical trials by applying for phase 1 ...
- US phase I clinical trials dose expansion part started in earnest.- Expect excellent anti-cancer effects and minimized toxic side effects with bispecific antibody of new mechanism. ABL Bio (CEO Sanghoon Lee), a company specializing in bispecific antibody, announced on the 7th that it has applied to the Ministry of Food and Drug Safety (MFDS) for the phase 1 clinical trial IND of the bispecific antibody immuno-oncology ABL503. This is to proceed with the dose expansion part, the next step after the dose escalation part of the phase 1 clinical trial currently ongoing in the United States, about two years after applying for phase 1 clinical trial in the US at the end of 2020. ABL Bio plans to secure additional safety data in solitary therapy and determine recommended phase 2 does (RP2D) and optimal target cancer through dose expansion part clinical trials conducted at Korea clinical institutions with 6 US clinical institutions. ABL503, which is applied with Grabbody-T platform technology, is a bispecific antibody immuno-oncology that targets PD-L1 and 4-1BB at the same time, and is currently under joint development with NASDAQ-listed company I-Mab. Although it cannot be disclosed in detail yet, it is said to be raising expectations as it is showing good results in both efficacy and toxicity in phase 1 clinical trials in the US, which is currently in the part of a dose escalation. 4-1BB, which helps activate T cells, is known to have excellent anticancer effects, but high toxic side effects when administered as a single antibody are pointed out as limitation. However, in the case of ABL503 bispecific antibody, 4-1BB can be activated in immune cells around cancer cells expressing PD-L1, so it is possible to minimize the toxic side effects of 4-1BB through selective T-cell activation only in the tumor microenvironment. ABL Bio Sanghoon Lee CEO said, "The US phase 1 clinical trial of ABL111 with 4-1BB-based Grabbody-T platform technology is also showing good progress," adding, "Starting with ABL503 and ABL111, many of the company's Grabbody-T-based pipelines, including ABL103, will be the center of attention." Through this, we will be able to become a leading company in the field of bisepecific antibody for T-cell engagement," he said. Meanwhile, ABL Bio is developing BBB shuttle platform Grabody-B, which is also applied to ABL301, and various pipelines using it as a new drug for degenerative brain diseases, and is developing many pipelines based on 4-1BB-based Grabbody-T in the field of immuno-oncology. Among them, ABL111 is conducting phase 1 clinical trials in the US and China, and ABL103 is expected to enter phase 1 clinical trials this year.
2023-02-07ablbio
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bisp...
- South Korea’s MFDS clears IND application for a Phase 1 study evaluating the safety and preliminary efficacy of ABL501 as a monotherapy for solid tumor treatment- ABL’s third IND this year for bispecific antibody therapeutics August 4, 2021, SEONGNAM, South Korea - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced that the Investigational New Drug (IND) application for ABL501 has been approved by South Korea’s Ministry of Food and Drug Safety (MFDS). The Phase 1 clinical trial is an open-label, multi-center dose escalation and dose expansion study designed to evaluate the safety, tolerability, maximum tolerated dose (MTD) and preliminary efficacy of ABL501 in patients with advanced or metastatic solid tumors. ABL501 uses Grabody-I platform technology to simultaneously block PD-L1 and LAG-3-mediated T cell inhibition. Preclinical results demonstrate a synergistic increase of T cell activation that is higher than the enhancements induced by combination of anti-PD-L1 and LAG-3. ABL501 also showed a good safety profile in monkeys. “LAG-3 is emerging as a promising target for cancer immunotherapy. We look forward to verifying ABL501’s potential as a best-in-class bispecific antibody that overcomes the limitations of current LAG-3 targeting antibodies,” said Sang Hoon Lee, Ph.D., CEO of ABL Bio. “This is already our third IND approval this year, demonstrating our strong commitment to building a robust portfolio of bispecific antibody immunotherapies. Carrying on this momentum, we expect to submit multiple additional INDs next year.” About ABL BioABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com ABL ContactsInvestor InquiriesHyunjun Kiminvestor.relations@ablbio.com+82 31 8018 9845 Media InquiriesHee Jun Parkmedia.relations@ablbio.com+82 31 8014 7032
2021-08-04ablbio
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL50...
- ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile- ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors July 9, 2021 - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of pre-clinical data highlighting the safety and anti-tumor efficacy of ABL503/TJ-L14B in the Journal for ImmunoTherapy of Cancer(JITC). Jointly developed with I-Mab (NASDAQ: IMAB), ABL503 is a bispecific antibody combining PD-L1 checkpoint pathway with 4-1BB agonistic activity to overcome the current limitation of PD-(L)1 therapy and 4-1BB related toxicity. Using ABL’s Grabody-T bispecific antibody platform technology, ABL503 induces 4-1BB activation only in the presence of PD-L1 expressing tumors to minimize the risk of 4-1BB related peripheral toxicity. ABL503 is currently being evaluated in a Phase 1 study in the U.S. in patients with locally advanced or metastatic solid tumors (NCT04762641). The paper, “Novel anti-4-1BB X PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade,” was published in collaboration with Su-Hyung Park, PhD, Professor at the KAIST Graduate School of Medical Science and Engineering. The paper highlights key in vitro and in vivo research that demonstrate ABL503’s potential as a promising immunotherapeutic agent against cancer. In the study, ABL503 induced complete tumor regression in humanized mice, which was superior to anti-PD-L1 or anti-4-1BB monotherapy. Moreover, no tumor growth was observed in these mice when they were rechallenged at 40 days after their first ABL503 treatment, demonstrating that ABL503 treatment yields a prolonged anti-tumor response despite a short-term administration schedule. In addition, ABL503 was well-tolerated following a repeated high dose administration of ABL503 in monkeys. Monkeys treated with ABL503 exhibited overall good tolerance with normal liver functions. “These published data validate our Grabody-T platform technology to achieve anti-tumor efficacy with a low risk of off-tumor liver toxicity and support the therapeutic value of ABL503 as a potential best-in-class treatment for cancer,” said Sang Hoon Lee, Ph.D., CEO of ABL Bio. “We have great expectations for the program and look forward to further evaluating ABL503 in our Phase 1 study with I-Mab.” About ABL Bio ABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com ABL ContactsInvestor InquiriesHyunjun Kiminvestor.relations@ablbio.com+82 31 8018 9845 Media InquiriesHee Jun Parkmedia.relations@ablbio.com+82 31 8014 7032
2021-07-09ablbio
ABL Bio Announces the Publication of Paper Reviewing Bispecific Antibody-Based Cancer Immuno...
- Review paper describing the development status of bispecific antibodies published in Vaccines- ABL Bio to continue to expand its ‘Grabody’ bispecific antibody platform to bring effective immunotherapy options to patients July 5, 2021 - ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of a peer-reviewed review paper in Vaccines highlighting the potential of bispecific antibodies as the next generation cancer treatment. Co-authored by Professor Seung-Woo Lee of the Department of Life Sciences at POSTECH and his team, the paper is titled “Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies.” In the review, bispecific antibodies are classified into four categories: immune effector cell redirectors, tumor-targeted immunomodulators, dual immunomodulators, and dual tumor-targeting BsAbs. The paper provides an overview of each of these immunotherapies in clinical development as well as strategies to help overcome limitations. “We are delighted to see our review paper published in Vaccines in collaboration with ABL Bio, a company pioneering research and development efforts in the field of bispecific antibodies,” said Professor Seung-Woo Lee. “We expect this paper to provide key insights into the current status of the development of bispecific antibodies, believed to be the next generation of immunotherapies for cancer patients.” ABL Bio has developed a set of innovative bispecific antibody platforms and pipelines. Among them, ABL503 (PD-L1 X 4-1BB) and ABL111 (Claudin18.2 X 4-1BB), bispecifics that utilize ‘Grabody-T’ platform technology are currently in Phase 1 clinical trials in the U.S. An investigational new drug (IND) application for ABL501 (LAG-3 X PD-L1) has also been submitted recently to the Ministry of Food and Drug Safety in South Korea. Multiple additional programs are expected to enter clinical trials next year. “The global market for bispecific antibodies is continuously expanding, reflected in the increasing number of new clinical studies and the recent licensing deals signed by global pharmaceutical companies,” said Sang Hoon Lee, Ph.D., CEO of ABL Bio. “We plan to continue to expand our Grabody platforms to build a more robust bispecific antibody portfolio that can offer safe and promising treatment options.” About ABL Bio ABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com
2021-07-05ablbio